Posts Tagged ‘Featured’

Glycovax Pharma has been granted a strategic licence by the NRC to develop a semisynthetic vaccine targeting Pseudomonas aeruginosa — a high-priority pathogen according to the WHO, responsible for severe hospital-acquired infections. This vaccine aims to protect vulnerable individuals, especially those living with cystic fibrosis. Continue reading…

Glycovax Pharma Inc. is starting the large-scale production of a new glycolipidic vaccine adjuvant developed by the National Research Council of Canada (NRC). The NRC license has allowed Glycovax to optimize SLA manufacturing by developing a fully synthetic process meeting Good Manufacturing Practices (GMP). Continue reading…